Ikaika (Kai) Keli’iho’omalu is a 3rd generation Native-Hawaiian cannabis cultivator and entrepreneur from Puna on the Big Island of Hawai’i where he first learned to cultivate cannabis from his father and extended family. Since then, Ikaika has gone on to extend his career in cannabis starting his own cannabis cultivation business at the age of 25 as well as working for a number of other cannabis cultivators and micro-businesses. Ikaika has been a vocal advocate for social justice and equity in the cannabis industry both in California where he chaired the youth seat on the San Francisco Cannabis Legalization Task Force for two years as well as at home in Hawai’i where he has advocated for Native-Hawaiians and craft growers alike. Ikaika now has 13 years of experience in large-scale cannabis horticulture and business spanning multiple medical cannabis markets including Oregon, California, Hawai’i, and British Columbia. Ikaika has worked with a range of cultivation methodologies from advanced hydroponic techniques to Korean Natural Farming and No-till. He now oversees the cultivation department as Cultivation Manager at Helius Therapeutics state-of-the-art GACP cultivation facility based in Auckland, Aotearoa/New Zealand.
Andrew has more than 20 years’ experience working in business media both in NZ and Australia. During the course of his career he has interviewed more than 1,000 CEOs, business leaders and authors and has travelled to more than 50 countries.
A freelance writer and corporate speaker/MC, Andrew admits to being a self-confessed ‘news junkie’ and bookworm and has a wide range of interests particularly technology, business innovation and commercialisation, entrepreneurship, and the future of work.
He holds a Bachelor of Commerce degree and a Master’s in Business Commercialisation & Entrepreneurship from the University of Auckland.
Drawing on nearly three decades experience at global agribusiness Nufarm (ASX: NUF), and as the founding Chairman of MCIA, Cann Group’s CEO Peter Crock is shaping the future of the medicinal cannabis industry in Australia. With Peter at the helm and working closely with an experienced board of directors, Cann Group (ASX: CAN) received the first commercial cultivation licence in Australia, and was the first medicinal cannabis company to successfully list via an Initial Public Offering (IPO) on the Australian Securities Exchange (ASX), raising AUD$13.5 million.
To accelerate its growth, Cann Group has completed subsequent capital raisings totalling more than AUD$125m, which has enabled the advancement of its’ most ambitious project to date; a controlled environment, automated production facility which will be capable of producing up to 70,000kg of medicinal cannabis products per year when at full capacity.
With deep knowledge and experience in the areas of marketing, business and technology development, as well as mergers and acquisitions, Peter has overseen the growth and advancement of Cann Group.
In chairing the MCIA, Australia’s peak industry body for medicinal cannabis, Peter is well versed in the management of regulatory framework in both Australia, and abroad.
Bonni Goldstein, MD is the Medical Director of Canna-Centers Wellness & Education, a California-based medical practice devoted to educating patients about the use of cannabis for serious and chronic medical conditions. After years of working in the specialty of Pediatric Emergency medicine, she developed an interest in the science of medical cannabis after witnessing its beneficial effects in an ill friend. Over the last 13 years she has evaluated thousands of patients for use of medical cannabis and is recognized as an expert in the clinical application of cannabis therapeutics. She has a special interest in treating children with intractable epilepsy, autism, cancer and other serious conditions. Her latest book, “Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain” was published in September 2020 by Little, Brown Spark.
Is the Clinical Trial Manager at the Centre of Drug Repurposing and Medicines Research at the University of Newcastle.
She is responsible for managing new and ongoing clinical trials for the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), a National Health and Medical Research Council Centre of Research Excellence, to support quality evidence for the use of cannabis medicines.
This includes the NSW-wide study, Cannabinoids for Symptom Control in Advanced Cancer, An Open Label Prospective Clinical Trial in NSW (CARE NSW), funded by NSW Health through the NSW Clinical Cannabis Medicines Program.
ACRE provides Rachel with the opportunity to combine her research passions of natural product pharmacology; consumer reported outcomes and the design and execution of quality clinical trials.
Her early career included a PhD in New Zealand on the dietary chemoprevention of Pacific Island foods, before she moved to Australia and undertook pre-clinical and clinical research with isolated natural compounds. This, together with her subsequent coordination of the Australian Corneal Graft Registry and a large international multisite cancer trial for TROG Cancer Research, provided her with the necessary skills, understanding and appreciation of the complexities a clinical trial of cannabis medicines involve.
Dr. Adele Hosseini, Chief Scientific Officer at Bod Australia, has over 18 years’ experience leading the delivery of successful clinical trials including first in human pharmaceuticals and medical devices. Dr. Hosseini has also been involved in many aspects of healthcare including academia such as university lecturing, product development within pharmaceutical, biotech, medical device. She is a pioneer in the Australian medicinal cannabis industry-leading Bod Australia’s Scientific Advisory Board and research program. Over the last three years Dr. Hosseini has developed a deep understanding of medicinal cannabis and continues to development of new strategic direction and development of clinical trials and programs for pharmaceutical cannabis for multiple therapeutic indications for public health benefit.
Paul Mavor – Health House International
Paul is a registered Australian and UK pharmacist. His company Health House was granted the first medicinal cannabis import license in Australia and he is currently distributing medicinal cannabis products to eligible patients. Over the last 30 years he has owned several retail pharmacies and worked both in Australia and the UK. In the last 5 years he has focused on researching medicinal cannabis and has been to conferences, grow and manufacturing facilities and spoken to patients and prescribers in the United States, United Kingdom, Canada, Israel and South America. www.healthhouse.com.au